TerrAscend (TSNDF) Cash from Investing Activities (2021 - 2026)
TerrAscend's (TSNDF) quarterly Cash from Investing Activities came in at $4000.0 in Q1 2026, up 100.14% year-on-year from $1998.6 in Q1 2025, and up 100.35% on a QoQ basis from -$1.1 million in Q4 2025.
TerrAscend (TSNDF) Cash from Investing Activities (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Cash from Investing Activities data on file, last reported at $4000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 100.14% year-over-year to $4000.0 in Q1 2026; TTM through Mar 2026 was -$11.6 million, a 1.13% increase from a year earlier, with the FY2025 full-year figure at -$14.6 million, down 19.27% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $4000.0, up from -$1.1 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for TSNDF reached as high as $13.9 million in Q1 2022 and fell as low as -$22.7 million in Q3 2023.
- Historically, Cash from Investing Activities has averaged -$4.8 million across 5 years, with a median of -$3.1 million in 2025.
- Across the five-year window, Cash from Investing Activities jumped 207.98% in 2022 and tumbled 605.09% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$15.0 million in 2022, then surged by 108.25% to $1.2 million in 2023, then tumbled by 605.09% to -$6.2 million in 2024, then soared by 81.71% to -$1.1 million in 2025, then soared by 100.35% to $4000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $4000.0 in Q1 2026, -$1.1 million in Q4 2025, and -$3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | TerrAscend | 164.05 Mn | 163.57 Mn | 34.60 Mn | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -1.14 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Sep 30, 2025 | -3.08 Mn |
| Sep 30, 2025 | -3.08 Mn |
| Jun 30, 2025 | -7.43 Mn |
| Jun 30, 2025 | -7.43 Mn |
| Mar 31, 2025 | -2.96 Mn |
| Mar 31, 2025 | -2.96 Mn |
| Dec 31, 2024 | -6.25 Mn |
| Dec 31, 2024 | -6.25 Mn |
| Sep 30, 2024 | -956,000.00 |
| Sep 30, 2024 | -956,000.00 |
| Jun 30, 2024 | -1.62 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Dec 31, 2023 | 1.24 Mn |